Literature DB >> 7945311

N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase.

J L Boucher1, J Custot, S Vadon, M Delaforge, M Lepoivre, J P Tenu, A Yapo, D Mansuy.   

Abstract

N omega-Hydroxy-L-arginine (L-NOHA) is a potent inhibitor of the hydrolysis of L-arginine (L-Arg) to L-ornithine (L-Orn) catalyzed by purified bovine liver arginase (BLA). It appears as one of the most powerful arginase inhibitors reported so far (Ki = 150 microM). The other products of NO synthase are either without effect (NO2-, NO3-) or much weaker inhibitors (L-citrulline (L-Cit) and NO) of BLA. Products derived from a possible hydrolysis of L-Arg (L-Orn and urea) or of L-NOHA (L-Cit, hydroxyurea and hydroxylamine) are also inactive toward BLA at concentrations up to 2 mM. The configuration of L-NOHA is important as D-NOHA is much less active, and its free -COOH and alpha-NH2 functions are required for recognition of BLA. L-NOHA is also a potent inhibitor of the arginase activity of rat liver homogenates and of murine macrophages (IC50 of 150 and 450 microM, respectively). These remarkable properties of L-NOHA could play a role in the modulation of the biosynthesis of the biological mediator NO by increasing local L-Arg concentrations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945311     DOI: 10.1006/bbrc.1994.2371

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

1.  Endothelial arginase II responds to pharmacological inhibition by elevation in protein level.

Authors:  Karina Krotova; Jawaharlal M Patel; Edward R Block; Sergey Zharikov
Journal:  Mol Cell Biochem       Date:  2010-06-19       Impact factor: 3.396

Review 2.  Arginase: a critical regulator of nitric oxide synthesis and vascular function.

Authors:  William Durante; Fruzsina K Johnson; Robert A Johnson
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-09       Impact factor: 2.557

Review 3.  Recent advances in arginine metabolism: roles and regulation of the arginases.

Authors:  Sidney M Morris
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

Review 4.  Arginase and vascular aging.

Authors:  Lakshmi Santhanam; David W Christianson; Daniel Nyhan; Dan E Berkowitz
Journal:  J Appl Physiol (1985)       Date:  2008-08-21

Review 5.  Nitric oxide and redox mechanisms in the immune response.

Authors:  David A Wink; Harry B Hines; Robert Y S Cheng; Christopher H Switzer; Wilmarie Flores-Santana; Michael P Vitek; Lisa A Ridnour; Carol A Colton
Journal:  J Leukoc Biol       Date:  2011-01-13       Impact factor: 4.962

Review 6.  Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors.

Authors:  Khaled S Abdelkawy; Kelsey Lack; Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

7.  The effects of exogenous amino acids on the relaxant responses of pig urethral smooth muscle evoked by stimulation of the inhibitory nitrergic nerves.

Authors:  N Tugba Durlu; Alison F Brading
Journal:  Pflugers Arch       Date:  2004-10-05       Impact factor: 3.657

8.  Arginase blockade protects against hepatic damage in warm ischemia-reperfusion.

Authors:  Geetha Jeyabalan; John R Klune; Atsunori Nakao; Nicole Martik; Guoyao Wu; Allan Tsung; David A Geller
Journal:  Nitric Oxide       Date:  2008-04-14       Impact factor: 4.427

9.  Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression.

Authors:  S Peter Bak; Anselmo Alonso; Mary Jo Turk; Brent Berwin
Journal:  Mol Immunol       Date:  2008-09-27       Impact factor: 4.407

10.  Inhibition of L-arginine metabolizing enzymes by L-arginine-derived advanced glycation end products.

Authors:  Ying-Ling Lai; Sae Aoyama; Ryoji Nagai; Noriyuki Miyoshi; Hiroshi Ohshima
Journal:  J Clin Biochem Nutr       Date:  2010-02-27       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.